Sermorelin Results: What Is Actually Documented
People searching this want to know what to expect. The honest answer is that the documented evidence and the marketed promise are about two different things, and the gap between them is the whole story.
- TwoFDA approvals sermorelin ever held — neither of them in adults
- SurrogateWhat a rising IGF-1 is — a marker the drug acted, not a result you can feel
- No controlWhat every before-and-after photograph is missing
- None foundApproval-grade trials of sermorelin for the adult uses it is sold for
The short version
Sermorelin has a documented record, and it is real. It is also about children with a diagnosed growth hormone deficiency, and about a one-off test of whether a pituitary gland responds. Neither is the thing being sold to adults today.
For the uses clinics actually market — body composition, energy, sleep quality, recovery, ageing — we could not find trial evidence of the kind that would support an approval. That does not mean nothing happens when someone takes it. It means the results being promised have not been demonstrated to the standard the rest of this site holds drugs to, and the honest thing is to say so rather than fill the gap with photographs.
The approval history itself, with sources and application numbers, is on our sermorelin overview. This page is about what the evidence can and cannot tell you.
What the documented evidence actually measured
- Whether a pituitary gland responds. The first approval was a diagnostic — a single administration to see whether the gland releases growth hormone when signalled. The measured result is a hormone reading. Nobody was expected to feel anything, and nothing about long-term use follows from it.
- Whether children with a deficiency grew. The second approval covered idiopathic growth hormone deficiency in children with growth failure. The measured result is height gain, in children whose own production was diagnosed as inadequate.
- What was not measured. Body fat, lean mass, sleep, energy, recovery, skin, libido or wellbeing in healthy adults. Not because the trials failed on those measures — because those trials were not the ones run.
Why “it worked in children” does not transfer
Correcting a diagnosed deficiency in a growing child and topping up a normal level in a healthy 45-year-old are different interventions with different biology and different risk profiles. Evidence for the first is not evidence for the second. This is the single most common move in sermorelin marketing, and it does not hold.
The blood test that gets shown as proof
A clinic will often measure IGF-1 before and after and present the rise as evidence the treatment is working. The rise is usually real. What it demonstrates is narrower than it looks.
IGF-1 is a surrogate marker. A rise shows the drug did the biological thing it is supposed to do — the signal reached the pituitary, growth hormone went up, and IGF-1 followed. It does not show that your body composition changed, that you sleep better, or that anything happened you would notice. Surrogate markers are useful precisely because they move early and are easy to measure; they are unreliable precisely because moving a marker and improving an outcome are different achievements, and medicine has a long history of drugs that did the first without the second.
And a raised IGF-1 is not purely good news
IGF-1 is a growth factor — a signal telling cells to divide. The approved labelling of the one drug still marketed in this class states that the effects of prolonged elevations in IGF-1 are unknown. A number going up is being sold as the result; the label treats the same number going up, and staying up, as an open question. We cover that in full on sermorelin side effects.
Why before-and-after photographs cannot answer this
Most of what is published under this heading is photographs and testimonials. We do not publish those, and the reason is not squeamishness — it is that they cannot distinguish the drug from everything else that happened. Four problems, all of which apply even when everyone involved is completely sincere.
- Nobody is being compared to anybody. Without a control group there is no way to know what would have happened anyway. This is exactly what a placebo arm exists for, and every trial figure elsewhere on this site is reported against one.
- Something else almost always changed too. People starting a peptide protocol usually also start eating differently, training, sleeping more and paying attention. Those work. Nothing in a photograph separates their contribution from the drug’s.
- You are only shown the ones that worked. Nobody publishes the photographs of the people who felt no different. The published set is selected after the fact, which makes it uninformative about your odds no matter how many images there are.
- People start when they feel worst. Treatment tends to begin at a low point, and low points tend to be followed by improvement regardless. That statistical pull toward the average is enough on its own to produce a convincing pair of photographs.
None of this means the people in those photographs are lying, or that they did not change. It means the photographs cannot tell you whether the drug is why — which is the only question worth asking before paying for it.
What would count as an answer
It is worth being concrete about what we are waiting for, because “there is no evidence” is easy to say and easy to dismiss. A study that would change this page would look like the ones we report on the GLP-1 drugs: healthy adults of the age actually being treated, randomly assigned to sermorelin or placebo, neither they nor the assessors knowing which, running long enough for a real change, measuring an outcome people care about rather than a hormone level, and reporting how many people dropped out.
That is not an unreasonable bar. It is the bar every drug we cover elsewhere on this site has cleared, and their results are published dose by dose with confidence intervals and dropout rates attached. If a study of that kind is published for sermorelin, we will report it here, whichever way it goes.
Until then, the accurate summary is: documented for a diagnostic test and for children with a diagnosed deficiency; undocumented, at that standard, for everything it is currently sold to do.
What this page will not tell you
- How much weight you will lose, or how you will look after three months. Nobody can tell you that from the evidence that exists, and anyone offering a figure is inventing it.
- Before-and-after photographs or testimonials, for the reasons set out above.
- What amount to take, or for how long. There is no approved product, supply is compounded, and concentrations vary by pharmacy.
- That sermorelin does not work. We have not found evidence that it does what is claimed, which is a different statement, and we will update this page if that changes.
Sources and method
- The approvals and their exact indications. Taken from the FDA’s own records and set out with application numbers and dates on our sermorelin overview. The wording of each indication is quoted there rather than paraphrased.
- The IGF-1 labelling. Quoted from the approved labelling of the currently marketed drug in this class, as set out on sermorelin side effects.
- What we could not find, stated as such. We searched for randomised, placebo-controlled trials of sermorelin in healthy adults measuring body composition, sleep, energy or recovery, and did not find evidence at approval standard. That is the outcome of a search, not proof that no such study exists anywhere — if you know of one, we would genuinely like to see it.
- Method. This page reports the absence of evidence as an absence rather than filling it with material that looks like evidence. Testimonials, photographs and surrogate markers are described as what they are. Where a claim rests on a search returning nothing, that is stated rather than presented as a finding.
Sermorelin overview → Sermorelin side effects → How we source and verify →
Reviewed 5 September 2026. We recheck this page if a controlled trial of sermorelin in healthy adults is published.